{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T18:40:15Z","timestamp":1741891215849,"version":"3.38.0"},"reference-count":40,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"published-print":{"date-parts":[[2024,3,29]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> SARS-CoV-2 seroprevalence monitors cumulative infection rates irrespective of case testing protocols. We aimed to describe Nova Scotia blood donor seroprevalence in relation to public health policy and reported data over the course of the COVID-19 pandemic (May 2020 to August 2022). <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> Monthly random Nova Scotia blood donation samples (24,258 in total) were tested for SARS-CoV-2 infection antibodies (anti-nucleocapsid) from May 2020 to August 2022, and vaccination antibodies (anti-spike) from January 2021 to August 2022. Multivariable logistic regression for infection antibodies and vaccination antibodies separately with month, age, sex, and racialization identified independent predictors. The provincial nucleic acid amplification test (NAAT)-positive case rate over the pandemic was calculated from publicly available data. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Anti-N seroprevalence was 3.8% in January 2022, increasing to 50.8% in August 2022. The general population COVID-19 case rate was 3.5% in January 2022, increasing to 12.5% in August 2022. The percentage of NAAT-positive samples in public health laboratories increased from 1% in November 2021 to a peak of 30.7% in April 2022 with decreasing numbers of tests performed. Higher proportions of younger donors as well as Black, Indigenous, and racialized blood donors were more likely to have infection antibodies ( p &lt; 0.01). Vaccination antibodies increased to 100% over 2021, initially in older donors (60+ years), and followed by progressively younger age groups. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> SARS-CoV-2 infection rates were relatively low in Nova Scotia until the more contagious Omicron variant dominated, after which about half of Nova Scotia donors had been infected despite most adults being vaccinated (although severity was much lower in vaccinated individuals). Most COVID-19 cases were detected by NAAT until Omicron arrived. When NAAT testing priorities focused on high-risk individuals, infection rates were better reflected by seroprevalence. <\/jats:p><\/jats:sec>","DOI":"10.3138\/jammi-2023-0017","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T14:00:01Z","timestamp":1711980001000},"page":"32-45","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 seroprevalence in Nova Scotia blood donors"],"prefix":"10.3138","volume":"9","author":[{"given":"Sheila F","family":"O\u2019Brien","sequence":"first","affiliation":[{"name":"Epidemiology & Surveillance, Canadian Blood Services, Ottawa, Ontario, Canada"},{"name":"School of Epidemiology & Public Health, University of Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley L","family":"Deeks","sequence":"additional","affiliation":[{"name":"Department of Health and Wellness, Government of Nova Scotia, Halifax, Nova Scotia, Canada"},{"name":"Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Hatchette","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Nova Scotia Health, Central Zone, Halifax, Nova Scotia, Canada"},{"name":"Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantale","family":"Pambrun","sequence":"additional","affiliation":[{"name":"Medical Affairs & Innovation, Canadian Blood Services, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J","family":"Drews","sequence":"additional","affiliation":[{"name":"Microbiology, Canadian Blood Services, Edmonton, Alberta, Canada"},{"name":"Department of Pathology & Laboratory Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1696","reference":[{"key":"r1","unstructured":"Statistics Canada. Preliminary dataset on confirmed cases of COVID-19. Public Health Agency of Canada (statcan.gc.ca) (Accessed March 14, 2023)."},{"key":"r2","doi-asserted-by":"crossref","first-page":"104433","DOI":"10.1016\/j.jcv.2020.104433","volume":"128","author":"LeBlanc JJ","year":"2020","journal-title":"J Clin Virol"},{"key":"r3","unstructured":"Nova Scotia Health. COVID-19 testing. https:\/\/www.nshealth.ca\/coronavirustesting. (Accessed May 5, 2023)."},{"issue":"3","key":"r4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/vox.12995","volume":"116","author":"O\u2019Brien SF","year":"2021","journal-title":"Vox Sang"},{"issue":"14","key":"r5","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2021.15161","volume":"326","author":"Jones JM","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"r6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/infdis\/jiab566","volume":"225","author":"Kaspersen KA","year":"2022","journal-title":"J Infect Dis"},{"issue":"6","key":"r7","doi-asserted-by":"crossref","first-page":"e0252617","DOI":"10.1371\/journal.pone.0252617","volume":"16","author":"Bobrovitz N","year":"2021","journal-title":"PLoS One"},{"issue":"11","key":"r8","doi-asserted-by":"crossref","first-page":"e1004107","DOI":"10.1371\/journal.pmed.1004107","volume":"19","author":"Bergeri I","year":"2022","journal-title":"PLoS Med"},{"key":"r9","unstructured":"The COVID-19 Immunity Task Force. https:\/\/www.covid19immunitytaskforce.ca\/ (Accessed March 14, 2023)"},{"issue":"47","key":"r10","doi-asserted-by":"crossref","first-page":"E1599","DOI":"10.1503\/cmaj.221335","volume":"194","author":"Skowronski DM","year":"2022","journal-title":"CMAJ"},{"issue":"1","key":"r11","doi-asserted-by":"crossref","first-page":"e0029121","DOI":"10.1128\/Spectrum.00291-21","volume":"9","author":"Charlton CL","year":"2021","journal-title":"Microbiol Spectr"},{"issue":"9","key":"r12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/23744235.2022.2080250","volume":"54","author":"Kanji JN","year":"2022","journal-title":"Infect Dis (Lond)"},{"issue":"50","key":"r13","doi-asserted-by":"crossref","first-page":"2001559","DOI":"10.2807\/1560-7917.ES.2021.26.50.2001559","volume":"26","author":"Bolotin S","year":"2021","journal-title":"Euro Surveill"},{"key":"r14","unstructured":"The Daily Statistics Canada. Between April and August 2022, 98% of Canadians had antibodies against COVID-19 and 54% had antibodies from a previous infection. https:\/\/www150.statcan.gc.ca\/n1\/en\/daily-quotidien\/230327\/dq230327b-eng.pdf?st=lLUfTidG (Accessed May 5, 2023)."},{"issue":"4","key":"r15","first-page":"24","volume":"33","author":"Bushnik T","year":"2022","journal-title":"Health Rep"},{"key":"r16","unstructured":"Statistics Canada. Table 13-10-0818-01 SARS-CoV-2 antibody seroprevalence in Canadians, by age group and sex, November 2020 to April 2021 (Accessed December 27, 2022)."},{"key":"r17","unstructured":"Canpath. COVID-19 Initiatives. https:\/\/canpath.ca\/covid-19-initiatives\/ (Accessed March 14, 2023)."},{"issue":"2","key":"r18","doi-asserted-by":"crossref","first-page":"e2146798","DOI":"10.1001\/jamanetworkopen.2021.46798","volume":"5","author":"Tang X","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"24","key":"r19","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMc2202879","volume":"386","author":"Brown PE","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"r20","doi-asserted-by":"crossref","first-page":"e0033922","DOI":"10.1128\/spectrum.00339-22","volume":"10","author":"Reedman CN","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"11","key":"r21","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.3390\/v14112336","volume":"14","author":"O\u2019Brien SF","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"r22","doi-asserted-by":"crossref","first-page":"e0335622","DOI":"10.1128\/spectrum.03356-22","volume":"11","author":"O\u2019Brien SF","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"31","key":"r23","doi-asserted-by":"crossref","first-page":"E1030","DOI":"10.1503\/cmaj.230249","volume":"195","author":"Murphy TJ","year":"2023","journal-title":"Can Med Assoc J"},{"key":"r24","unstructured":"SARS-CoV-2 Immunoassay | Core Laboratory at Abbott (Accessed March 15, 2023)."},{"key":"r25","unstructured":"Elecsys\u00ae Anti-SARS-CoV-2 S. Package Insert 2020-09, V1.0; Material Numbers09289267190 and 09289275190."},{"key":"r26","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/BF03403824","volume":"103","author":"Pampalon R","year":"2012","journal-title":"Can J Public Health"},{"issue":"4","key":"r27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.24095\/hpcdp.29.4.05","volume":"29","author":"Pampalon R","year":"2009","journal-title":"Chronic Dis Can"},{"key":"r28","unstructured":"Github. A definitive dataset for COVID-19 in Canada. ccodwg\/CovidTimelineCanada (Accessed May 10, 2023)."},{"key":"r29","unstructured":"COVID-19 vaccination in Canada. https:\/\/health-infobase.canada.ca\/covid-19\/vaccination-coverage\/ (Accessed March 14, 2023)."},{"key":"r30","unstructured":"Canadian Institute for Health Information. Canadian COVID-19 intervention timeline. Available at: https:\/\/www.cihi.ca\/en\/canadian-covid-19-intervention-timeline"},{"issue":"1","key":"r31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.prevetmed.2013.09.015","volume":"113","author":"Lang Z","year":"2014","journal-title":"Prev Vet Med"},{"issue":"4","key":"r32","doi-asserted-by":"crossref","first-page":"e045425","DOI":"10.1136\/bmjopen-2020-045425","volume":"11","author":"Grant R","year":"2021","journal-title":"BMJ Open"},{"issue":"3","key":"r33","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/joim.13304","volume":"290","author":"Castro-Dopico X","year":"2021","journal-title":"J Intern Med"},{"issue":"2","key":"r34","doi-asserted-by":"crossref","first-page":"E305","DOI":"10.9778\/cmajo.20220045","volume":"11","author":"Atkinson A","year":"2023","journal-title":"CMAJ Open"},{"issue":"2","key":"r35","doi-asserted-by":"crossref","first-page":"ofab632","DOI":"10.1093\/ofid\/ofab632","volume":"9","author":"Duarte N","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"r36","unstructured":"Approved COVID-19 vaccines. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/covid19-industry\/drugs-vaccines-treatments\/vaccines.html (Accessed March 14, 2023)."},{"issue":"1","key":"r37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/infdis\/jiab514","volume":"225","author":"Dodd RY","year":"2022","journal-title":"J Infect Dis"},{"issue":"2","key":"r38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3934\/microbiol.2023015","volume":"9","author":"Harne R","year":"2023","journal-title":"AIMS Microbiol"},{"issue":"6","key":"r39","doi-asserted-by":"crossref","first-page":"E195","DOI":"10.1503\/cmaj.211249","volume":"194","author":"Xia Y","year":"2022","journal-title":"CMAJ"},{"issue":"3","key":"r40","doi-asserted-by":"crossref","first-page":"E599","DOI":"10.9778\/cmajo.20220031","volume":"10","author":"Anand SS","year":"2022","journal-title":"CMAJ Open"}],"container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/jammi-2023-0017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T17:58:47Z","timestamp":1741888727000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/jammi-2023-0017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3,29]]}},"alternative-id":["10.3138\/jammi-2023-0017"],"URL":"https:\/\/doi.org\/10.3138\/jammi-2023-0017","relation":{},"ISSN":["2371-0888","2371-0888"],"issn-type":[{"type":"print","value":"2371-0888"},{"type":"electronic","value":"2371-0888"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}